Last reviewed · How we verify
MDI FP
MDI FP is a metered-dose inhaler formulation of fluticasone propionate that delivers corticosteroid directly to the airways to reduce inflammation and airway obstruction.
MDI FP is a metered-dose inhaler formulation of fluticasone propionate that delivers corticosteroid directly to the airways to reduce inflammation and airway obstruction. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | MDI FP |
|---|---|
| Sponsor | Imperial College London |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a potent inhaled corticosteroid that binds to glucocorticoid receptors in airway epithelial and immune cells, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. The MDI (metered-dose inhaler) delivery system ensures consistent dose administration to the lungs. This mechanism reduces airway hyperresponsiveness and improves airflow in obstructive airway diseases.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia
- Tremor
- Headache
- Throat irritation
Key clinical trials
- Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) (PHASE4)
- Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma (PHASE3)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate (PHASE4)
- The Clinical Effect of Monodisperse Fluticasone Propionate in Asthma (PHASE4)
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MDI FP CI brief — competitive landscape report
- MDI FP updates RSS · CI watch RSS
- Imperial College London portfolio CI